{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:49Z","timestamp":1791828589703,"version":"4.3.4"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2024-0597_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The primary goal in managing glycogen storage disorders (GSD) is to implement dietary therapy through regular glucose monitoring while attempting to prevent complications. Self-monitoring of blood glucose is often insufficient for detecting asymptomatic hypoglycemia in patients. Therefore, Continuous glucose monitoring systems (CGMS) play a crucial role in identifying hypoglycemic episodes and providing detailed glucose profiles throughout the day. In this study, CGMS data, laboratory findings, and daily nutritional intake were examined in patients with GSDIa and GSDIII. The lack of similar studies in GSDIII patients in the literature highlights the need for further research in this field.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0597_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The glucose profiles of 12 patients (7 GSDIa and 5 GSDIII) were analyzed over a 72\u202fh period using CGMS. Nutritional intake, biochemical parameters, and growth parameters were also evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0597_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study demonstrated that CGMS detected both hypoglycemia (&lt;70\u202fmg\/dL) and hyperglycemia (&gt;150\u202fmg\/dL) in GSD patients. Growth retardation was also observed in\u00a0these patients. As complications of the disease, elevated levels of liver enzymes, cholesterol, triglycerides, and creatine kinase were identified, with fatty liver and hepatomegaly detected in all patients. The patients\u2019 nutritional intake is similar to the recommendations in disease-specific treatment guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0597_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The primary dietary treatment goal for GSD\u00a0patients is to maintain normoglycemia. Patients may experience asymptomatic low glucose and\/or asymptomatic hypoglycemic episodes during treatment. CGMS enables a more detailed monitoring of glucose profiles, which not only facilitates the precise adjustment of dietary therapy based on detailed results but also helps prevent complications associated with the disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2024-0597","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T06:40:35Z","timestamp":1741416035000},"page":"458-464","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of continuous glucose monitoring and nutritional status in glycogen storage diseases"],"prefix":"10.1515","volume":"38","author":[{"given":"Burcu","family":"Kumru Akin","sequence":"first","affiliation":[{"name":"Division of Nutrition and Diet , Gaziantep Cengiz Gok\u00e7ek Maternity and Children\u2019s Hospital , Gaziantep , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine","family":"Goksoy","sequence":"additional","affiliation":[{"name":"Division of Pediatric Metabolism , Adnan Menderes University , Ayd\u0131n , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"2025082013043674574_j_jpem-2024-0597_ref_001","doi-asserted-by":"crossref","unstructured":"Herbert, M, Pendyal, S, Rairikar, M, Halaby, C, Benjamin, RW, Kishnani, PS. Role of continuous glucose monitoring in the management of glycogen storage disorders. J Inherit Metab Dis 2018;41:917\u201327. https:\/\/doi.org\/10.1007\/s10545-018-0200-5.","DOI":"10.1007\/s10545-018-0200-5"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_002","doi-asserted-by":"crossref","unstructured":"Kishnani, PS, Austin, SL, Arn, P, Bali, DS, Boney, A, Case, LE, et al.. Glycogen storage disease type III diagnosis and management guidelines. Genet Med 2010;12:446\u201363. https:\/\/doi.org\/10.1097\/gim.0b013e3181e655b6.","DOI":"10.1097\/GIM.0b013e3181e655b6"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_003","doi-asserted-by":"crossref","unstructured":"Rousseau-Nepton, I, Huot, C, Laforte, D, Mok, E, Fenyves, D, Constantin, E, et al.. Sleep and quality of life of patients with glycogen storage disease on standard and modified uncooked cornstarch. Mol Genet Metabol 2018;123:326\u201330. https:\/\/doi.org\/10.1016\/j.ymgme.2017.09.003.","DOI":"10.1016\/j.ymgme.2017.09.003"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_004","doi-asserted-by":"crossref","unstructured":"Massimino, E, Amoroso, AP, Lupoli, R, Rossi, A, Capaldo, B. Nutritional management of glycogen storage disease type III: a case report and a critical appraisal of the literature. Front Nutr 2023;10. https:\/\/doi.org\/10.3389\/fnut.2023.1178348.","DOI":"10.3389\/fnut.2023.1178348"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_005","doi-asserted-by":"crossref","unstructured":"Steunenberg, TAH, Peeks, F, Hoogeveen, IJ, Mitchell, JJ, Mundy, H, de Boer, F, et al.. Safety issues associated with dietary management in patients with hepatic glycogen storage disease. Mol Genet Metabol 2018;125:79\u201385. https:\/\/doi.org\/10.1016\/j.ymgme.2018.07.004.","DOI":"10.1016\/j.ymgme.2018.07.004"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_006","doi-asserted-by":"crossref","unstructured":"Fukuda, T, Ito, T, Hamazaki, T, Inui, A, Ishige, M, Kagawa, R, et al.. Blood glucose trends in glycogen storage disease type Ia: a cross-sectional study. J Inherit Metab Dis 2023;46:618\u201333. https:\/\/doi.org\/10.1002\/jimd.12610.","DOI":"10.1002\/jimd.12610"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_007","doi-asserted-by":"crossref","unstructured":"Vashist, SK. Continuous glucose monitoring systems: a review. Diagnostics 2013;3:385\u2013412. https:\/\/doi.org\/10.3390\/diagnostics3040385.","DOI":"10.3390\/diagnostics3040385"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_008","doi-asserted-by":"crossref","unstructured":"Hochuli, M, Christ, E, Meienberg, F, Lehmann, R, Kr\u00fctzfeldt, J, Baumgartner, MR. Alternative nighttime nutrition regimens in glycogen storage disease type I: a controlled crossover study. J Inherit Metab Dis 2015;38:1093\u20138. https:\/\/doi.org\/10.1007\/s10545-015-9864-2.","DOI":"10.1007\/s10545-015-9864-2"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_009","doi-asserted-by":"crossref","unstructured":"Kasapkara, \u00c7S, Cinasal Demir, G, Hasano\u011flu, A, T\u00fcmer, L. Continuous glucose monitoring in children with glycogen storage disease type I. Eur J Clin Nutr 2014;68:101\u20135. https:\/\/doi.org\/10.1038\/ejcn.2013.186.","DOI":"10.1038\/ejcn.2013.186"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_010","doi-asserted-by":"crossref","unstructured":"White, F, Jones, S. The use of continuous glucose monitoring in the practical management of glycogen storage disorders. J Inherit Metab Dis 2011;34:631\u201342. https:\/\/doi.org\/10.1007\/s10545-011-9335-3.","DOI":"10.1007\/s10545-011-9335-3"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_011","doi-asserted-by":"crossref","unstructured":"Lang, TA, Altman, DG. Basic statistical reporting for articles published in biomedical journals: the \u201cstatistical analyses and methods in the published literature\u201d or the SAMPL guidelines. Int J Nurs Stud 2015;52:5\u20139. https:\/\/doi.org\/10.1016\/j.ijnurstu.2014.09.006.","DOI":"10.1016\/j.ijnurstu.2014.09.006"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_012","doi-asserted-by":"crossref","unstructured":"Blevins, TC. Professional continuous glucose monitoring in clinical practice 2010. J Diabetes Sci Technol 2010;4:440. https:\/\/doi.org\/10.1177\/193229681000400226.","DOI":"10.1177\/193229681000400226"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_013","doi-asserted-by":"crossref","unstructured":"Bergenstal, RM, Beck, RW, Close, KL, Grunberger, G, Sacks, DB, Kowalski, A, et al.. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care 2018;41:2275\u201380. https:\/\/doi.org\/10.2337\/dc18-1581.","DOI":"10.2337\/dc18-1581"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_014","doi-asserted-by":"crossref","unstructured":"Kaiser, N, Gautschi, M, Bosanska, L, Meienberg, F, Baumgartner, MR, Spinas, GA, et al.. Glycemic control and complications in glycogen storage disease type I: results from the Swiss registry. Mol Genet Metabol 2019;126:355\u201361. https:\/\/doi.org\/10.1016\/j.ymgme.2019.02.008.","DOI":"10.1016\/j.ymgme.2019.02.008"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_015","doi-asserted-by":"crossref","unstructured":"dos Santos, BB, Nalin, T, Grokoski, KC, Perry, IDS, Refosco, LF, Vairo, FP, et al.. Nutritional status and body composition in patients with hepatic glycogen storage diseases treated with uncooked cornstarch\u2014a controlled study. J Inborn Errors Metab Screen 2017;5:1\u20137. https:\/\/doi.org\/10.1177\/2326409817733014.","DOI":"10.1177\/2326409817733014"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_016","doi-asserted-by":"crossref","unstructured":"Weinstein, D, Wolfsdorf, J. Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr 2002;161:S35\u20139. https:\/\/doi.org\/10.1007\/s00431-002-1000-2.","DOI":"10.1007\/s00431-002-1000-2"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_017","doi-asserted-by":"crossref","unstructured":"Kishnani, PS, Austin, SL, Abdenur, JE, Arn, P, Bali, DS, Boney, A, et al.. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med 2014;16:1\u201329. https:\/\/doi.org\/10.1038\/gim.2014.128.","DOI":"10.1038\/gim.2014.128"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_018","doi-asserted-by":"crossref","unstructured":"Melis, D, Pivonello, R, Cozzolino, M, Della Casa, R, Balivo, F, Del Puente, A, et al.. Impaired bone metabolism in glycogen storage disease type 1 is associated with poor metabolic control in type 1a and with granulocyte colony-stimulating factor therapy in type 1b. Horm Res Paediatr 2014;81:55\u201362. https:\/\/doi.org\/10.1159\/000351022.","DOI":"10.1159\/000351022"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_019","doi-asserted-by":"crossref","unstructured":"Mundy, HR, Hindmarsh, PC, Matthews, DR, Leonard, JV, Lee, PJ. The regulation of growth in glycogen storage disease type 1. Clin Endocrinol 2003;58:332\u20139. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01717.x.","DOI":"10.1046\/j.1365-2265.2003.01717.x"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_020","doi-asserted-by":"crossref","unstructured":"Jorge, NB, de Tommaso, AMA, Hessel, G. Anthropometric and dietary assessment of patients with glycogenosis type I. Rev Paul Pediatr 2021;39. https:\/\/doi.org\/10.1590\/1984-0462\/2021\/39\/2020046.","DOI":"10.1590\/1984-0462\/2021\/39\/2020046"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_021","doi-asserted-by":"crossref","unstructured":"Rossi, A, Ruoppolo, M, Formisano, P, Villani, G, Albano, L, Gallo, G, et al.. Insulin-resistance in glycogen storage disease type Ia: linking carbohydrates and mitochondria? J Inherit Metab Dis 2018;41:985\u201395. https:\/\/doi.org\/10.1007\/s10545-018-0149-4.","DOI":"10.1007\/s10545-018-0149-4"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_022","doi-asserted-by":"crossref","unstructured":"Jellinger, PS. Metabolic consequences of hyperglycemia and insulin resistance. Clin Cornerstone 2007;8:30\u201342. https:\/\/doi.org\/10.1016\/s1098-3597(07)80019-6.","DOI":"10.1016\/S1098-3597(07)80019-6"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_023","doi-asserted-by":"crossref","unstructured":"Battelino, T, Danne, T, Bergenstal, RM, Amiel, SA, Beck, R, Biester, T, et al.. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42:1593\u2013603. https:\/\/doi.org\/10.2337\/dci19-0028.","DOI":"10.2337\/dci19-0028"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_024","doi-asserted-by":"crossref","unstructured":"Peeks, F, Hoogeveen, IJ, Feldbrugge, RL, Burghard, R, de Boer, F, Fokkert-Wilts, MJ, et al.. A retrospective in-depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: recommended outcome parameters for glucose management. J Inherit Metab Dis 2021;44:1136\u201350. https:\/\/doi.org\/10.1002\/jimd.12383.","DOI":"10.1002\/jimd.12383"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_025","doi-asserted-by":"crossref","unstructured":"Rossi, A, Venema, A, Haarsma, P, Feldbrugge, L, Burghard, R, Rodriguez-Buritica, D, et al.. A prospective study on continuous glucose monitoring in glycogen storage disease type ia: toward glycemic targets. J Clin Endocrinol Metab 2022;107:E3612\u201323. https:\/\/doi.org\/10.1210\/clinem\/dgac411.","DOI":"10.1210\/clinem\/dgac411"},{"key":"2025082013043674574_j_jpem-2024-0597_ref_026","doi-asserted-by":"crossref","unstructured":"Garbade, SF, Ederer, V, Burgard, P, Wendel, U, Spiekerkoetter, U, Haas, D, et al.. Impact of glycogen storage disease type I on adult daily life: a survey. Orphanet J Rare Dis 2021;16:1\u201310. https:\/\/doi.org\/10.1186\/s13023-021-02006-w.","DOI":"10.1186\/s13023-021-02006-w"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2024-0597\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2024-0597\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:05:25Z","timestamp":1755695125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2024-0597\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,20]]},"published-print":{"date-parts":[[2025,5,26]]}},"alternative-id":["10.1515\/jpem-2024-0597"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2024-0597","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]}}}